Literature DB >> 16863562

Possible association between isotretinoin and inflammatory bowel disease.

Deepa Reddy1, Corey A Siegel, Bruce E Sands, Sunanda Kane.   

Abstract

OBJECTIVES: The Physician's Desk Reference lists inflammatory bowel disease (IBD) as a possible adverse event associated with the use of isotretinoin, a popular acne prescription medication. Our aim was to perform a systematic examination of reports of IBD associated with isotretinoin use.
METHODS: All reports filed with the Food and Drug Administration (FDA) via the MedWatch system were requested and reviewed. Strength of causality was determined using the Naranjo adverse drug reaction (ADR) probability scale.
RESULTS: All of the adverse reports filed with the FDA between 1997 and 2002 were accessed and reviewed. Eighty-five cases of IBD associated with isotretinoin use were reported. According to the Naranjo ADR probability scale, 4 cases (5%) scored in the "highly probable" range for isotretinoin as the cause of IBD, 58 cases (68%) were "probable," 23 cases (27%) were "possible," and no cases were "doubtful."
CONCLUSIONS: In a subgroup of patients, isotretinoin might serve as a trigger for IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863562     DOI: 10.1111/j.1572-0241.2006.00632.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  30 in total

1.  Advances In IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-03

2.  Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/+ Mice.

Authors:  Hweixian Leong Penny; Tyler R Prestwood; Nupur Bhattacharya; Fionna Sun; Justin A Kenkel; Matthew G Davidson; Lei Shen; Luis A Zuniga; E Scott Seeley; Reetesh Pai; Okmi Choi; Lorna Tolentino; Jinshan Wang; Joseph L Napoli; Edgar G Engleman
Journal:  Cancer Immunol Res       Date:  2016-09-16       Impact factor: 11.151

3.  Isotretinoin use and the risk of inflammatory bowel disease: a case-control study.

Authors:  Seth D Crockett; Carol Q Porter; Christopher F Martin; Robert S Sandler; Michael D Kappelman
Journal:  Am J Gastroenterol       Date:  2010-03-30       Impact factor: 10.864

4.  Isotretinoin use and celiac disease: a population-based cross-sectional study.

Authors:  Benjamin Lebwohl; Anders Sundström; Bana Jabri; Sonia S Kupfer; Peter H R Green; Jonas F Ludvigsson
Journal:  Am J Clin Dermatol       Date:  2014-12       Impact factor: 7.403

5.  Immunology: Context is key in the gut.

Authors:  Craig L Maynard; Casey T Weaver
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

Review 6.  Epigenetic regulation of T helper cells and intestinal pathogenicity.

Authors:  Yuya Hagihara; Yusuke Yoshimatsu; Yohei Mikami; Yoshiaki Takada; Shinta Mizuno; Takanori Kanai
Journal:  Semin Immunopathol       Date:  2019-03-19       Impact factor: 9.623

7.  Anti-Fibrotic Potential of All Trans Retinoic Acid in Inflammatory Bowel Disease.

Authors:  Dominick L Auci; Nejat K Egilmez; Gerald W Dryden
Journal:  J Gastroenterol Pancreatol Liver Disord       Date:  2018-05-28

Review 8.  Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System.

Authors:  Derrick J Stobaugh; Parakkal Deepak; Eli D Ehrenpreis
Journal:  Eur J Clin Pharmacol       Date:  2012-10-06       Impact factor: 2.953

9.  Isotretinoin, acne, and Crohn's disease: a convergence of bad skin, bad science, and bad litigation creates the perfect storm.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

10.  Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Authors:  Raed O Alhusayen; David N Juurlink; Muhammad M Mamdani; Richard L Morrow; Neil H Shear; Colin R Dormuth
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.